- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01405794
In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
25. maj 2016 opdateret af: mark munger, University of Utah
The investigators propose to study oral commercial silver nanoparticle products on human enzyme activity.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
12
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112-5820
- University of Utah
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 80 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- 18-80 years old without debilitating chronic disease or history of cardiovascular event.
Exclusion Criteria:
- Women physically capable of becoming pregnant, who are not using 2 barrier methods of birth control;
- Any female who is nursing;
- History of heavy metal allergy;
- History of asthma or Chronic Obstructive Pulmonary Disease;
- History of renal impairment;
- Symptoms of active upper respiratory disease at time of consent;
- Smoking more than 5 cigarettes or equivalent and not able to stop for 48 hours;
- Ability to discontinue chronic medications or nutraceuticals for 20 days or 5 half-lives of the agent, whichever is longer.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Ikke-randomiseret
- Interventionel model: Crossover opgave
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: 32ppm Oral Silver
14 Days Active Silver Solution
|
Oral silver dose of 32ppm
|
Placebo komparator: Sterile Water
No Silver Nanoparticles
|
Sterile Water No Silver
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change Sodium Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change Potassium Blood Levels
Tidsramme: 14 days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 days
|
Change in Chloride Blood Levels
Tidsramme: 14 days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 days
|
Change in Carbon Dioxide Blood Levels
Tidsramme: 14 days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 days
|
Change In Urea Nitrogen Blood Levels
Tidsramme: 14 days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 days
|
Change In Creatinine Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Glucose Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Alkaline Phosphatase Blood Level
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Aspartate Aminotransferase Blood Level
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Alanine Aminotransferase Blood Level
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change in Total Protein Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Total Bilirubin Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Albumin Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Calcium Blood Level
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In White Blood Count Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Red Blood Count Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Hemoglobin Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Hematocrit Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Mean Corpuscular Volume Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Mean Corpuscular Hemoglobin Concentration Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Platelet Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Granulocytes Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Lymphocytes Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Monocytes Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Basophils Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Change In Eosinophils Blood Levels
Tidsramme: 14 Days
|
Evaluation of Placebo Group and Silver Particle Group (dose - 32ppm)
|
14 Days
|
Cytochrome P450 Assay on Dextromethorphan in Participants
Tidsramme: 14 Days
|
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days).
Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized.
The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
|
14 Days
|
Cytochrome P450 Assay on Losartan in Participants
Tidsramme: 14 Days
|
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days).
Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized.
The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
|
14 Days
|
Cytochrome P450 Assay on Caffeine in Participants
Tidsramme: 14 Days
|
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days).
Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized.
The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
|
14 Days
|
Cytochrome P450 Assay on Omeprazole in Participants
Tidsramme: 14 Days
|
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days).
Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized.
The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
|
14 Days
|
Cytochrome P450 Assay on Midazolam in Participants
Tidsramme: 14 Days
|
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days).
Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized.
The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
|
14 Days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Cytochrome P450 Assay on Chlorozoxazone in Participants Dosed With Silver
Tidsramme: 14 Days
|
Assessment Placebo (14 Days) and 32ppm Oral Silver (14 Days).
Cytochrome P450 assay is used to determine the function of how Dextromethorphan metabolized.
The value represents the peak absorption of the 450 enzyme when dextromethorphan is given during the Silver or Placebo Arm.
|
14 Days
|
Total Change in Systolic Blood Pressure Silver Participants
Tidsramme: Baseline and 14 Days
|
Assessment only completed on the 32ppm Oral Silver part of the trail
|
Baseline and 14 Days
|
Total Change in Diastolic Blood Pressure Silver Participants
Tidsramme: Baseline and 14 Days
|
Assessment only completed on the 32ppm Oral Silver part of the trail
|
Baseline and 14 Days
|
Total Change in Heart Rate in Silver Participants
Tidsramme: Baseline and 14 Days
|
Assessment only completed on the 32ppm Oral Silver part of the trail
|
Baseline and 14 Days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Mark Munger, Pharm.D., University of Utah
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2011
Primær færdiggørelse (Faktiske)
1. november 2011
Studieafslutning (Faktiske)
1. november 2011
Datoer for studieregistrering
Først indsendt
19. juli 2011
Først indsendt, der opfyldte QC-kriterier
28. juli 2011
Først opslået (Skøn)
29. juli 2011
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
4. juli 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
25. maj 2016
Sidst verificeret
1. september 2015
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 50310 (MSD Sharp&Dohme GmbH)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .